Mostrar el registro sencillo del ítem

Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study

dc.rights.licenseopenen_US
dc.contributor.authorLEBOYER, Marion
dc.contributor.authorGODIN, Ophelia
dc.contributor.authorTERRO, Emilie
dc.contributor.authorBOUKOUACI, Wahid
dc.contributor.authorLU, Ching-Lieng
dc.contributor.authorANDRE, Myrtille
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorAOUIZERATE, Bruno
IDREF: 069471851
dc.contributor.authorBERNA, Fabrice
dc.contributor.authorBARAU, Caroline
dc.contributor.authorCAPDEVIELLE, Delphine
dc.contributor.authorCLAUSS-KOBAYASHI, Julie
dc.contributor.authorCHEREAU, Isabelle
dc.contributor.authorD′AMATO, Thierry
dc.contributor.authorDUBERTRET, Caroline
dc.contributor.authorDUBREUCQ, Julien
dc.contributor.authorFOND, Guillaume
dc.contributor.authorLAOUAMRI, Hakim
dc.contributor.authorLEIGNIER, Sylvain
dc.contributor.authorLANCON, Christophe
dc.contributor.authorLLORCA, Pierre-Michel
dc.contributor.authorMALLET, Jasmina
dc.contributor.authorLE CORVOISIER, Philippe
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorMISDRAHI, David
dc.contributor.authorPASSERIEUX, Christine
dc.contributor.authorREY, Romain
dc.contributor.authorPIGNON, Baptiste
dc.contributor.authorURBACH, Mathieu
dc.contributor.authorSZOKE, Andrei
dc.contributor.authorSCHURHOFF, Franck
dc.contributor.authorTAMOUZA, Ryad
dc.date.accessioned2023-06-07T07:42:17Z
dc.date.available2023-06-07T07:42:17Z
dc.date.issued2021-04-27
dc.identifier.issn2632-7899en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182511
dc.description.abstractEnTreatment-resistant schizophrenia (TRS) affects around 30% of patients with schizophrenia (SZ) resulting in poor functioning, relapses, and reduced quality of life. Convergent findings show that inflammation could contribute to resistance. We thus search for immune signatures of patients with TRS/ultra TRS (UTRS) in a sample of community-dwelling outpatients with SZ. In total, 195 stabilized SZ patients (mean age = 31.2 years, 73% male gender) were consecutively included in the network of the FondaMental Expert Centers for Schizophrenia in France and received a thorough clinical assessment. At inclusion, psychotic symptomatology was evaluated by the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Circulating serum/plasma levels of a large panel of markers reflecting the main inflammatory pathways were evaluated. TRS was defined by current treatment by clozapine (CLZ) and UTRS by current CLZ treatment + PANSS total score ≥ 70. The frequency of TRS and UTRS patients was, respectively, 20% and 7.7% and was defined using multivariable analysis elevated by high levels of interleukin (IL)-12/IL-23p40, IL-17A, IL-10, and beta 2 microglobulin (B2M) and IL-12/IL-23p40, IL-17A, IL-6, IL-10, IFNγ, and B2M, respectively. These observations suggest that resistance and ultra resistance to CLZ treatment are underpinned by pro-inflammatory molecules mainly belonging to the T helper 17 pathway, a finding making sense given the interplay between inflammation and antipsychotic treatment responses. If confirmed, our findings may allow us to consider IL-23/IL-17 pathway as a therapeutic target for patients with resistance to antipsychotics.
dc.description.sponsorshipSorbonne Universités à Paris pour l'Enseignement et la Rechercheen_US
dc.description.sponsorshipFondaMental-Cohortesen_US
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subject.enSchizophrenia
dc.subject.enImmuno-inflammatory
dc.subject.enSignatures
dc.subject.enProfile
dc.subject.enTreatment-resistant
dc.subject.enClozapine
dc.title.enImmune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study
dc.title.alternativeSchizophrenia Bulletin Openen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/schizbullopen/sgab012en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed34901861en_US
bordeaux.journalSchizophrenia Bulletin Openen_US
bordeaux.volume2en_US
bordeaux.hal.laboratoriesNutriNeuro (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINRAEen_US
bordeaux.institutionCNRS
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Schizophrenia%20Bulletin%20Open&rft.date=2021-04-27&rft.volume=2&rft.issue=1&rft.eissn=2632-7899&rft.issn=2632-7899&rft.au=LEBOYER,%20Marion&GODIN,%20Ophelia&TERRO,%20Emilie&BOUKOUACI,%20Wahid&LU,%20Ching-Lieng&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
NutriNeuro_SBO_2021_Leboyer.pdf
Tamaño:
202.6Kb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
920bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem